Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
ADNOC Gas Targets Up to $4B Profit in 2026 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Add as a preferred source on Google
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
